Halozyme Therapeutics Inc
NASDAQ:HALO
Net Margin
Halozyme Therapeutics Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | US |
| Market Cap | 5.7B USD |
| Net Margin |
37%
|
| Country | US |
| Market Cap | 293.9B USD |
| Net Margin |
9%
|
| Country | US |
| Market Cap | 167.5B USD |
| Net Margin |
13%
|
| Country | US |
| Market Cap | 114.7B USD |
| Net Margin |
37%
|
| Country | US |
| Market Cap | 108.2B USD |
| Net Margin |
29%
|
| Country | AU |
| Market Cap | 135.3B AUD |
| Net Margin |
17%
|
| Country | US |
| Market Cap | 84.1B USD |
| Net Margin |
2%
|
| Country | US |
| Market Cap | 50.7B USD |
| Net Margin |
-116%
|
| Country | US |
| Market Cap | 43.1B USD |
| Net Margin |
-33%
|
| Country | US |
| Market Cap | 33.5B USD |
| Net Margin |
12%
|
| Country | KR |
| Market Cap | 39.7T KRW |
| Net Margin |
25%
|
Profitability Report
View the profitability report to see the full profitability analysis for Halozyme Therapeutics Inc.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Halozyme Therapeutics Inc's most recent financial statements, the company has Net Margin of 37%.
You don't have any saved screeners yet
